Glargine versus regular insulin protocol in feline diabetic ketoacidosis

J Vet Emerg Crit Care (San Antonio). 2021 Jul;31(4):459-468. doi: 10.1111/vec.13062. Epub 2021 May 4.

Abstract

Objectives: To determine whether basal-bolus administration of glargine insulin is a safe and effective alternative treatment compared to the standard continuous rate infusion (CRI) protocol.

Design: Prospective randomized clinical trial.

Setting: University teaching hospital.

Animals: Twenty cats diagnosed with diabetic ketoacidosis (DKA).

Interventions: The cats were block-randomized to either a CRI protocol using regular insulin (CRI-group; n = 10) or a basal-bolus SC and IM glargine protocol (glargine-group, n = 10). Baseline blood gases, electrolytes, glucose, and β-hydroxybutyrate (β-OHB) concentrations were measured at the time of admission and later at predefined intervals until reaching the primary endpoint of the study, defined as a β-hydroxybutyrate concentration < 2.55 mmol/L.

Measurements and main results: The main outcome measure was time (h) to resolution of ketonemia. Secondary outcome measures were time until first improvement of hyperglycemia and ketonemia, decrease of glucose to ≤13.9 mmol/L (250 mg/dL), resolution of acidosis, consumption of first meal, and discharge from hospital. Additionally, occurrence of treatment-associated adverse events and death were compared. Seventeen cats (85%) survived to discharge, with no difference in survival between groups (P = 1.0). Median times to β-OHB < 2.55 mmol/L were 42 (CRI-group) and 30 (glargine-group) hours, respectively (P = 0.114). Median times to first improvement of hyperglycemia (glargine-group: 2 h; CRI-group: 6 h; P = 0.018) and until discharge from hospital (glargine-group: 140 h; CRI-group: 174 h; P = 0.033) were significantly shorter in the glargine-group. No significant differences were observed in any other parameter under investigation (P > 0.05).

Conclusions: Basal-bolus administration of glargine insulin appears to be an effective and safe alternative to the current standard CRI-protocol for the management of DKA in cats. The positive outcomes and simplicity make it a viable option for the treatment of feline DKA.

Keywords: diabetes mellitus; intramuscular; potassium; saline; β-hydroxybutyrate.

Publication types

  • Clinical Trial Protocol

MeSH terms

  • Animals
  • Blood Glucose
  • Cat Diseases* / drug therapy
  • Cats
  • Clinical Trials, Veterinary as Topic
  • Diabetic Ketoacidosis* / drug therapy
  • Diabetic Ketoacidosis* / veterinary
  • Hyperglycemia* / veterinary
  • Hypoglycemic Agents / therapeutic use
  • Insulin
  • Insulin Glargine / adverse effects
  • Prospective Studies

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Insulin Glargine